Auszug
Die wichtigsten Hormone des Nebennierenmarks sind die physiologisch aktiven Katecholamine Dopamin, Noradrenalin und Adrenalin. Außerhalb des Nebennierenmarks werden die Katecholamine im Gehirn, in den sympathischen Nervenendigungen und in den chromaffinen Geweben gebildet. Die wichtigsten Metabolite der Katecholamine sind Vanillin- und Homovanillinmandelsäure sowie Meta- und Normetanephrin, die im Urin ausgeschieden werden. Die Messung der Metanephrine und Katecholamine im Serum oder im Urin wird für die Diagnose hormonaktiver Tumoren des Nebennierenmarks oder des Grenzstrangs herangezogen.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Ambros PF, Ambros IM (2001) Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines. Med Pediatr Oncol 37: 492–504
Berthold F, Hero B (2000) Neuroblastoma: current drug therapy recommendations as part of the total treatment approach. Drugs 59: 1261–1277
Berthold F, Boos J, Budach S et al. (2005) Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol 6: 649–658
Brodeur GM, Pritohard J, Berthold F (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol 11: 1466–1477
Hoefnagel CA, Kraker L de, Valdes Olmos RA, Voute PA (1994) J-MIBG as a first-line treatment in high risk neuroblastoma patients. Nucl Med Communic 15: 712–717
Kushner BH, Kramer K, Cheung NK (2001) Phase II-trial of the anti-G (D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol 19: 4189–4194
Kushner BH, Kramer K, Modak S, Cheung NK (2006) Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. J Clin Oncol 24: 5271–5276
Matthay KK, Villablanca JG, Seeger RC et al. (1999) Treatment of high risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 341: 1165–1173
Oberthuer A, Berthold F, Warnat P et al. (2006) Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 24: 5070–5078
Schilling FH, Spix C, Berthold F et al. (2002) Neuroblastoma screening at one year of age. N Engl J Med 346: 1047–1053
Simon T, Langler A, Berthold F, Klingebiel T, Hero B (2007) Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: Results of a phase 2 trial. J Pediatr Hematol Oncol 29: 101–106
Spitz R, Hero B, Simon T, Berthold F (2006) Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma. Clin Cancer Res 12: 3368–3373
Woods WG, Gao RN, Shuster JJ et al. (2002) Screening of infants and mortality due to neuroblastoma. N Engl J Med 346: 1041–1046
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Dilloo, D., Göbel, U. (2007). Erkrankungen des Nebennierenmarks und des Grenzstrangs. In: Reinhardt, D. (eds) Therapie der Krankheiten im Kindes- und Jugendalter. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-71899-4_26
Download citation
DOI: https://doi.org/10.1007/978-3-540-71899-4_26
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-71898-7
Online ISBN: 978-3-540-71899-4
eBook Packages: Medicine (German Language)